Skip to Content

Join the 'Ozurdex' group to help and get support from people like you.

Ozurdex News

Drug Trio Shows Major Promise Against Myeloma

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who received a standard drug duo alone. And over 13.5 months, the daratumumab combination cut patients' risk of dying or seeing their cancer progress by 63 percent, the study found. Researchers called the results "unprecedented" for patients like these. All had relapsed or refractory myeloma – which means the cancer had either come back or failed to respond to the previous treatment. "It is very likely that (this regimen) will be rapidly adopted by practicing physicians," said lead researcher Dr. Meletios ... Read more

Related support groups: Dexamethasone, Multiple Myeloma, Revlimid, Decadron, TobraDex, Ciprodex, Maxitrol, Ozurdex, Osteolytic Bone Lesions of Multiple Myeloma, Decadron Tablets, Dexamethasone/Tobramycin, Tobradex ST, Dexamethasone/Neomycin/Polymyxin B, Lenalidomide, Dexone, Poly-Dex, Decadron Dose Pack, Dexpak Taperpak, Neo-Poly-Dex, Adrenocot LA

FDA Approves Revised Indication for Ozurdex for the Treatment of Diabetic Macular Edema

Posted 1 Oct 2014 by Drugs.com

IRVINE, Calif.-September 29, 2014 - Allergan, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Ozurdex (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME). Ozurdex was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). Based on ongoing review of clinical data demonstrating efficacy and safety, the FDA has now approved Ozurdex for use in the general DME patient population. "Allergan is committed to developing innovative treatment options that address unmet patient needs, and retinal diseases such as DME are extremely difficult to manage," said Scott M. Whitcup, M.D., Executive Vice President, Research and Development and Chief Scientific ... Read more

Related support groups: Dexamethasone, Ozurdex, Diabetic Macular Edema

Allergan Receives FDA Approval for Ozurdex as Treatment Option for Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Posted 29 Sep 2010 by Drugs.com

IRVINE, Calif.--(BUSINESS WIRE)--Sep 24, 2010 - Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved Ozurdex (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye. Uveitis is characterized by inflammation of the eye's uvea, which is the middle vascular layer consisting of the iris (anterior), ciliary body (intermediate) and choroid (posterior). Uveitis of the anterior (front) of the uvea is more common and typically does not lead to vision impairment;1 while posterior uveitis (back of the eye) is associated with more severe outcomes that can include blindness, cataracts, secondary glaucoma and macular abnormalities.2 Posterior uveitis is the cause of 10 to 15 percent of cases of blindness in the United States.3 Ozurdex is a biodegradable ... Read more

Related support groups: Uveitis, Ozurdex, Uveitis (Posterior)

Ask a Question

Further Information

Related Condition Support Groups

Diabetic Macular Edema, Macular Edema, Uveitis, Uveitis (Posterior)

Ozurdex Patient Information at Drugs.com